Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.71 |
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
| ▸ | CA2 | P00918 | 1/20 | 0.71 |
| ▸ | CA9 | Q16790 | 1/20 | 0.71 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.68 |
| ▸ | CDK1 | P06493 | 1/20 | 0.68 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.68 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.68 |
| ▸ | CDK2 | P24941 | 1/20 | 0.68 |
| ▸ | CDK7 | P50613 | 1/20 | 0.68 |
| ▸ | CCNH | P51946 | 1/20 | 0.68 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.68 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | XBP1 | P17861 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28560165 | 0.95 | CA12 (0.65) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL14877794 | 0.93 | CA12 (0.76) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL23057261 | 0.90 | IDO1 (0.72) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL31681311 | 0.89 | CA12 (0.66) | CA12CA1CA2CA9FFAR4 | |
| SCHEMBL259382 | 0.89 | CA12 (0.66) | CA12CA1CA2CA9FFAR4 | |
| SCHEMBL13875341 | 0.88 | L3MBTL1 (0.67) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL1592806 | 0.88 | LMNA (0.60) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL26463794 | 0.88 | CYP19A1 (0.78) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL2240551 | 0.88 | HTR6 (0.73) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL15045213 | 0.87 | KMT2A (0.71) | MEN1KMT2ALMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9670172-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9611230-B2 | 1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2017-04-04 | — | — | US | disclosed |
| EP-2301538-B1 | Compounds for nonsense suppression, and methods for their use | PTC THERAPEUTICS INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES LLC | 2015-03-05 | — | — | US | disclosed |
| US-20120118616-A1 | NEGATIVE PHOTOSENSITIVE RESIN COMPOSITION, POLYIMIDE RESIN FILM USING SAME, AND FLEXIBLE PRINTED CIRCUIT BOARD | SUMITOMO ELECTRIC PRINTED CIRCUITS, INC. (JP) | 2012-05-17 | — | — | US | disclosed |
| EP-2311455-A1 | Compounds for nonsense suppression, and methods for their use | PTC Therapeutics, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| EP-2301536-A1 | Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases | PTC Therapeutics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| EP-2301538-A1 | Compounds for nonsense suppression, and methods for their use | PTC Therapeutics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065519-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | HRAS, VHL, ESRRB | CA12 4106/4885CA1 4665/4885CA2 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.